The US Department of Health and Human Services announced that the government will invest $176 million in Moderna to expedite the creation of a pandemic influenza vaccine.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Moderna, the US biotech giant behind one of the world's leading COVID-19 vaccines, stands on the brink of expulsion from ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Scientists reveal what vaccines are really capable of As new COVID-19 variants continue to emerge, widespread concerns have ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

If found to be lacking adequate compliance systems, Moderna could ultimately be suspended or expelled from the Association of the British Pharmaceutical Industry (APBI). It follows several code ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Novavax faces uncertainty as FDA requests a new clinical trial for its COVID-19 vaccine, the last protein-based option in the ...

HHS Announces Plans to Pay Moderna $176 Million for mRNA Flu Vaccine By Stephanie Brown HealthDay Reporter FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and ...